Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven
“Key Takeaways: About a quarter of survey respondents who met USPSTF eligibility criteria were up to date with lung cancer screening in 2024 — an increase in prevalence of 6 percentage points since 2022. Lung cancer screening rates were low compared with those for other cancers, including colorectal, cervical, and breast cancers. Up-to-date prevalence was uneven depending on age, race and ethnicity, and insurance status.”
Chemotherapy-Free Regimens in First-Line NSCLC: Insights From ELCC 2026
“Research presented at ELCC 2026, held March 25 to March 28 in Copenhagen, Denmark, included a range of studies evaluating chemotherapy-free regimens for the first-line treatment of NSCLC. Abstracts described real-world studies of first-line osimertinib monotherapy in patients with EGFR-mutant NSCLC, updated results from the PALOMA-2 study (ClinicalTrials.gov identifier: NCT05498428) evaluating first-line subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced NSCLC, and long-term data from EMPOWER-Lung 1 (ClinicalTrials.gov identifier: NCT03088540) regarding first-line cemiplimab monotherapy in patients with advanced NSCLC and PD-L1 ≥50%, among others.”
Lung Cancer Pain Management Options
““Some people feel a dull ache or sharp pain when breathing deeply, coughing, or moving,” says Shunichi Nakagawa, MD, associate professor of medicine in the division of palliative care at Columbia University Vagelos College of Physicians and Surgeons in New York City. The pain can also be felt in the shoulder, upper back, and neck, especially if the tumor is close to nerves in these areas.”
Evolutionary characterization of lung cancer metastasis
“Limited understanding of the biological processes that govern metastatic dissemination hinders its prevention and treatment. Here, using 501 longitudinally collected primary and metastatic tumour samples from 24 patients with non-small cell lung cancer (NSCLC) enrolled in the TRACERx lung study and PEACE autopsy programme, we infer tumour evolution from diagnosis to death.”
Oncologist Exercise Advice Increases Physical Activity in Lung Cancer Patients
“Oncologist-delivered exercise recommendations were associated with increased levels of total physical exercise in patients with lung cancer, by approximately 270 minutes per week, measured at 8 weeks in a recent study. Findings were reported in the journal Cancer Medicine.”
How an enzyme helps lung cancer survive radiation, and how to stop it
“Researchers identified a mitochondrial enzyme that shields lung cancer cells from a radiation-induced cell death process — and then found that an existing arthritis drug can disable that shield.”
FDA Accepts NDA for Zipalertinib in EGFR Exon 20-Mutant Lung Cancer
“The FDA has accepted a new drug application (NDA) for zipalertinib (CLN-081), an oral, next-generation EGFR tyrosine kinase inhibitor (TKI). The application seeks approval for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations who have previously received systemic therapy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.”
Op-Ed: Firefighters face elevated cancer risk – Congress just took a critical step
“Two out of three firefighter deaths in the U.S. are related to cancer. This is why I was encouraged to see Congress earlier this year pass the Medicare Multi-Cancer Early Detection Screening Coverage Act, which was quickly signed into law.”
UB, Roswell Park develop AI tool to assess lung cancer surgery complication risk
“The system, called MIRACLE (Multimodal Integrated Radiomics and Clinical Language-based Explanation), is believed to be the first to combine clinical data, CT imaging and large language model (LLM)-generated explanations to provide personalized risk estimates for patients who may be candidates for lung cancer surgery. It also produces a summary that surgeons can review and refine to reflect their own clinical insight.”
Oncologists on TikTok: 10 Physicians Sharing Cancer Education Online
“Good communication and patient education are central to high-quality oncology care, but those conversations are no longer confined to the clinic. As patients increasingly turn to digital platforms for information, many are arriving at their health care appointments with perspectives shaped by algorithm-driven feeds that vary widely in accuracy, context, and tone.”
Innovative Lung-MAP Trial Expands to Include More Lung Cancer Patients
“Lung-MAP, a precision medicine umbrella trial for patients with advanced non-small cell lung cancer (NSCLC), has expanded genetic screening options for patients who enroll in this clinical trial of biomarker-driven therapies. The Friends of Cancer Research (Friends) hosted a webinar to explore how Lung-MAP is accelerating lung cancer discovery.”
65 % of eligible lung cancer patients do not receive the most appropriate targeted therapies, Diaceutics report finds
“Diaceutics, the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, has released new research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer (aNSCLC) in the US are still not receiving the most appropriate treatment.”
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
“Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by Flatiron Health. The research supports independent community oncologists’ ability to deliver high-quality outcomes for the majority of U.S. patients with cancer who receive care in community oncology settings.”
